Stifel Financial’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Stifel Financial’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-19,417	Closed	-$347K	–	2888
2018 Q3	$347K	Buy	+19,417	New	+$333K	﹤0.01%	2272
2017 Q2	–	Sell	-45,353	Closed	-$112K	–	2662
2017 Q1	$112K	Buy	45,353 +1,711	+4%	+$3.96K	﹤0.01%	2418
2016 Q4	$109K	Sell	43,642 -2,270	-5%	-$6.52K	﹤0.01%	2360
2016 Q3	$140K	Buy	45,912 +6,283	+16%	+$19.6K	﹤0.01%	2258
2016 Q2	$127K	Buy	+39,629	New	+$145K	﹤0.01%	2353
2014 Q3	–	Sell	-10,900	Closed	-$72K	–	2367
2014 Q2	$72K	Buy	10,900 +900	+9%	+$10.1K	﹤0.01%	2127
2014 Q1	$238K	Buy	+10,000	New	+$145K	﹤0.01%	1843

Other funds holding ECYT

OTC

Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return

Claro Advisors Boston, Massachusetts $830M AUM 21.8% 1-Year Est. Return

Stifel Financial's ECYT Position: Q4 2018 in Review

Stifel Financial sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 19,417 shares — an estimated $347K sold.

Stifel Financial first reported a position in ECYT in Q1 2014 and held it in 7 quarters. The position peaked at $347K in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

Stifel Financial reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Stifel Financial sold 19,417 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $347K.
Stifel Financial first reported a position in Endocyte, Inc. Common Stock in Q1 2014 and held it in 7 quarters.
Stifel Financial's Endocyte, Inc. Common Stock position peaked at $347K in Q3 2018.
2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on Stifel Financial's 13F filing for Q4 2018, filed 13 Feb 2019.